Alpha Tau reports promising Alpha DaRT trial results in pancreatic cancer and head and neck cancer, with significant survival benefits. High disease control rate (91% DCR) and positive interim safety ...
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results